Patient baseline characteristics
| Variable . | Value . | Included (n = 135) . | Not included (n = 440) . | P value . |
|---|---|---|---|---|
| Age (years) | Median (min-max) | 56 (35-65) | 55 (30-66) | .33 |
| Male | No. (%) | 109 (81) | 350 (80) | .81 |
| Stage | .55 | |||
| I | No. (%) | 0 (0) | 2 (0) | |
| II | No. (%) | 3 (2) | 20 (5) | |
| III | No. (%) | 16 (12) | 61 (14) | |
| IV | No. (%) | 116 (86) | 357 (81) | |
| B-symptoms | No. (%) | 51 (38) | 163 (37) | .92 |
| ECOG PS | .061 | |||
| 0-1 | No. (%) | 126 (93) | 428 (97) | |
| 2 | No. (%) | 9 (7) | 12 (3) | |
| Bone marrow involvement | No. (%) | 113 (84) | 323 (73) | .016 |
| Elevated LDH | No. (%) | 63 (47) | 147 (33) | .006 |
| LDH/ULN | Median (min-max) | 0.97 (0.41-4.8) | 0.89 (0.29-12.2) | .038 |
| WBC (G/L) | Median (min-max) | 8.8 (0.052-388) | 7.2 (1.1-1110) | .001 |
| MIPI score | Median (min-max) | 5.73 (3.63-8.03) | 5.51 (4.07-8.68) | <.001 |
| MIPI risk | <.001 | |||
| Low | No. (%) | 66 (49) | 294 (67) | |
| Intermediate | No. (%) | 35 (26) | 96 (22) | |
| High | No. (%) | 34 (25) | 50 (11) | |
| Ki-67 index (%)* | Median (min-max) | 19 (2-87) | 21 (0-97) | .52 |
| Ki-67 index ≥ 30% | No. (%) | 23 (32) | 63 (26) | .30 |
| Blastoid cytology† | No. (%) | 8 (9) | 22 (8) | .32 |
| Treatment | .83 | |||
| R-CHOP | No. (%) | 63 (47) | 174 (44)‡ | |
| R-CHOP/R-DHAP | No. (%) | 72 (53) | 217 (55)‡ |
| Variable . | Value . | Included (n = 135) . | Not included (n = 440) . | P value . |
|---|---|---|---|---|
| Age (years) | Median (min-max) | 56 (35-65) | 55 (30-66) | .33 |
| Male | No. (%) | 109 (81) | 350 (80) | .81 |
| Stage | .55 | |||
| I | No. (%) | 0 (0) | 2 (0) | |
| II | No. (%) | 3 (2) | 20 (5) | |
| III | No. (%) | 16 (12) | 61 (14) | |
| IV | No. (%) | 116 (86) | 357 (81) | |
| B-symptoms | No. (%) | 51 (38) | 163 (37) | .92 |
| ECOG PS | .061 | |||
| 0-1 | No. (%) | 126 (93) | 428 (97) | |
| 2 | No. (%) | 9 (7) | 12 (3) | |
| Bone marrow involvement | No. (%) | 113 (84) | 323 (73) | .016 |
| Elevated LDH | No. (%) | 63 (47) | 147 (33) | .006 |
| LDH/ULN | Median (min-max) | 0.97 (0.41-4.8) | 0.89 (0.29-12.2) | .038 |
| WBC (G/L) | Median (min-max) | 8.8 (0.052-388) | 7.2 (1.1-1110) | .001 |
| MIPI score | Median (min-max) | 5.73 (3.63-8.03) | 5.51 (4.07-8.68) | <.001 |
| MIPI risk | <.001 | |||
| Low | No. (%) | 66 (49) | 294 (67) | |
| Intermediate | No. (%) | 35 (26) | 96 (22) | |
| High | No. (%) | 34 (25) | 50 (11) | |
| Ki-67 index (%)* | Median (min-max) | 19 (2-87) | 21 (0-97) | .52 |
| Ki-67 index ≥ 30% | No. (%) | 23 (32) | 63 (26) | .30 |
| Blastoid cytology† | No. (%) | 8 (9) | 22 (8) | .32 |
| Treatment | .83 | |||
| R-CHOP | No. (%) | 63 (47) | 174 (44)‡ | |
| R-CHOP/R-DHAP | No. (%) | 72 (53) | 217 (55)‡ |
ECOG PS, Eastern Cooperative Oncology Group performance status; ULN, upper limit of normal range.
Ki-67 assessed in 72 of 135 included and in 245 of 440 not included patients.
Cytology assessed in 68 of 135 included and 270 of 440 not included patients.
In 48 patients treatment not documented, 1 R-bendamustin.